Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07239323 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Name: In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies — clinical trial record (NCT07239323)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorChongqing Precision Biotech Co., Ltd

Started2025-07-01

View on ClinicalTrials.gov ↗

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Non-Hodgkin Lymphoma

1,512 trials monitored

See 79 trials at risk

Multiple Myeloma

1,228 trials monitored

See 75 trials at risk

and 1 more disease

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.

Trial Details

NCT Number	NCT07239323
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
Enrollment	24 participants
Start Date	2025-07-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-20